| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
INVITED REVIEW
Department of Pathology and Laboratory of Medicine, University of Cincinnati, Cincinnati, Ohio
Cardiomyocytes respond to physiological or pathological stress only by hypertrophy and not by an increase in the number of functioning cardiomyocytes. However, recent evidence suggests that adult cardiomyocytes have the ability, albeit limited, to divide to compensate for the cardiomyocyte loss in the event of myocardial injury. Similarly, the presence of stem cells in the myocardium is a good omen. Their activation to participate in the repair process is, however, hindered by some as-yet-undetermined biological impediments. The rationale behind the use of adult stem cell transplantation is to supplement the inadequacies of the intrinsic repair mechanism of the heart and compensate for the cardiomyocyte loss in the event of injury. Various cell types including embryonic, fetal, and adult cardiomyocytes, smooth muscle cells, and stable cell lines have been used to augment the declining cardiomyocyte number and cardiac function. More recently, the focus has been shifted to the use of autologous skeletal myoblasts and bone marrow-derived stem cells. This review is a synopsis of some interesting aspects of the fast-emerging field of bone marrow-derived stem cell therapy for cardiac repair.
myocardial infarction; cardiomyocyte; plasticity; transdifferentiation
This article has been cited by other articles:
|
|
 |
|
  P. R. Crisostomo, Y. Wang, T. A. Markel, M. Wang, T. Lahm, and D. R. Meldrum Human mesenchymal stem cells stimulated by TNF-{alpha}, LPS, or hypoxia produce growth factors by an NF{kappa}B- but not JNK-dependent mechanism Am J Physiol Cell Physiol, March 1, 2008; 294(3): C675 - C682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Martinez-Marmol, M. David, R. Sanches, M. Roura-Ferrer, N. Villalonga, E. Sorianello, S. M. Webb, A. Zorzano, A. Guma, C. Valenzuela, et al. Voltage-dependent Na+ channel phenotype changes in myoblasts. Consequences for cardiac repair Cardiovasc Res, December 1, 2007; 76(3): 430 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Behfar and A. Terzic Cardioprotective repair through stem cell-based cardiopoiesis J Appl Physiol, October 1, 2007; 103(4): 1438 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Singla and D. E. McDonald Factors released from embryonic stem cells inhibit apoptosis of H9c2 cells Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1590 - H1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Singla, G. E. Lyons, and T. J. Kamp Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1308 - H1314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wang, P. R. Crisostomo, C. Herring, K. K. Meldrum, and D. R. Meldrum Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2006; 291(4): R880 - R884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fernandes, J.-C. Amirault, G. Lande, J.-M. Nguyen, V. Forest, O. Bignolais, G. Lamirault, D. Heudes, J.-L. Orsonneau, M.-F. Heymann, et al. Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias Cardiovasc Res, February 1, 2006; 69(2): 348 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Minguell and A. Erices Mesenchymal Stem Cells and the Treatment of Cardiac Disease Experimental Biology and Medicine, January 1, 2006; 231(1): 39 - 49. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
